{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:49:28Z","timestamp":1792615768091,"version":"4.5.0"},"reference-count":130,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Vet. Sci."],"abstract":"<jats:p>Diabetes mellitus is a common metabolic disease in humans and cats. Cats share several features of human type-2 diabetes and can be considered an animal model for this disease. In the last decade, sodium-glucose transporter 2 inhibitors (SGLT2i) have been used successfully as a class of hypoglycemic drug that inhibits the reabsorption of glucose from the renal proximal tubules, consequently managing hyperglycemia through glycosuria. Furthermore, SGLT2i have been shown to have cardiac, renal, and other protective effects in diabetic humans acting as a pleiotropic drug. Currently, at least six SGLT2i are approved by the Food and Drug Administration (FDA) for use in humans with type-2 diabetes, and recently, two drugs were approved for use in diabetic cats. This narrative review focuses on the use of SGLT2i to treat diabetes mellitus in humans and cats. We summarize the human data that support the use of SGLT2i in controlling type-2 diabetes and protecting against cardiovascular and renal damage. We also review the available literature regarding other benefits of these drugs in humans as well as the effects of SGLT2i in cats. Adverse effects related to the use of these hypoglycemic drugs are also discussed.<\/jats:p>","DOI":"10.3389\/fvets.2025.1480977","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T07:16:04Z","timestamp":1740726964000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Sodium-glucose co-transporter 2 inhibitors: a pleiotropic drug in humans with promising results in cats"],"prefix":"10.3389","volume":"12","author":[{"given":"Aline B.","family":"Vieira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M.","family":"Cavanaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca T.","family":"Ciambarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus V.","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s12551-015-0186-2","article-title":"Glucose transporters: physiological and pathological roles","volume":"8","author":"Navale","year":"2016","journal-title":"Biophys Rev"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1007\/s00424-020-02433-x","article-title":"Sodium-coupled glucose transport, the SLC5 family, and therapeutically relevant inhibitors: from molecular discovery to clinical application","volume":"472","author":"Gyimesi","year":"2020","journal-title":"Pflugers Archiv Eur J Physiol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1463-1326.2008.00982.x","article-title":"Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug","volume":"11","author":"Idris","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.pharmthera.2013.04.003","article-title":"Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data","volume":"139","author":"Kurosaki","year":"2013","journal-title":"Pharmacol Ther"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.mam.2012.07.001","article-title":"The SLC2 (GLUT) family of membrane transporters","volume":"34","author":"Mueckler","year":"2013","journal-title":"Mol Asp Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1111\/febs.15531","article-title":"A guide to plasma membrane solute carrier proteins","volume":"288","author":"Pizzagalli","year":"2021","journal-title":"FEBS J"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1681\/ASN.2020010071","article-title":"Quantitative proteomics of all 14 renal tubule segments in rat","volume":"31","author":"Limbutara","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/jlac.18350150105","article-title":"Ueber Das Phloridzin (Phlorrhizin)","volume":"15","author":"De Koninck","year":"1835","journal-title":"Annalen Der Pharmacie"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.3390\/molecules21091136","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibitors from natural products: discovery of next-generation antihyperglycemic agents","volume":"21","author":"Choi","year":"2016","journal-title":"Molecules (Basel, Switzerland)"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1007\/s00125-018-4656-5","article-title":"Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2","volume":"61","author":"Ghezzi","year":"2018","journal-title":"Diabetologia"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"6355","DOI":"10.1021\/jm100332n","article-title":"Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus","volume":"53","author":"Nomura","year":"2010","journal-title":"J Med Chem"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/jlcr.4091","article-title":"Carbon 14 and carbon 13 syntheses of velagliflozin","volume":"67","author":"Latli","year":"2024","journal-title":"J Label Compound Radiopharm"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.medcli.2024.01.027","article-title":"Effect of Empagliflozin in peripheral diabetic neuropathy of patients with type 2 diabetes mellitus","volume":"163","author":"El-Haggar","year":"2024","journal-title":"Med Clin"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s13300-024-01538-1","article-title":"Risk of dementia in patients with diabetes using sodium-glucose transporter 2 inhibitors (SGLT2i): a systematic review, meta-analysis, and meta-regression","volume":"15","author":"Gunawan","year":"2024","journal-title":"Diab Therapy Res Treat Educ Diab Relat Disord"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s41581-024-00836-y","article-title":"Applications of SGLT2 inhibitors beyond glycaemic control","volume":"20","author":"O\u2019Hara","year":"2024","journal-title":"Nat Rev Nephrol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"7213","DOI":"10.3390\/molecules26237213","article-title":"Neuroprotective effect of SGLT2 inhibitors","volume":"26","author":"Pawlos","year":"2021","journal-title":"Molecules (Basel, Switzerland)"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s13300-024-01550-5","article-title":"SGLT2 inhibitors - the new standard of care for cardiovascular, renal and metabolic protection in type 2 diabetes: a narrative review","volume":"15","author":"Seidu","year":"2024","journal-title":"Diab Therapy Res Treat Educ Diab Relat Disord"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1111\/dom.13648","article-title":"Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis","volume":"21","author":"Toyama","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/dom.12578","article-title":"Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition","volume":"18","author":"Rajeev","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.2337\/dc13-0387","article-title":"Characterization of renal glucose reabsorption in response to Dapagliflozin in healthy subjects and subjects with type 2 diabetes","volume":"36","author":"DeFronzo","year":"2013","journal-title":"Diabetes Care"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"7833","DOI":"10.3390\/ijms21217833","article-title":"Molecular mechanisms of SGLT2 inhibitor on cardiorenal protection","volume":"21","author":"Hou","year":"2020","journal-title":"Int J Mol Sci"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1530\/EC-20-0082","article-title":"Improvement of skeletal muscle insulin sensitivity by 1 week of SGLT2 inhibitor use","volume":"9","author":"Goto","year":"2020","journal-title":"Endocr Connect"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1681\/ASN.2013060588","article-title":"Functional role of glucose metabolism, osmotic stress, and sodium-glucose cotransporter isoform-mediated transport on Na+\/H+ exchanger isoform 3 activity in the renal proximal tubule","volume":"25","author":"Pessoa","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"ref25","first-page":"1661","article-title":"Diabetic nephropathy: early detection, prevention and management","volume":"45","author":"Maher","year":"1992","journal-title":"Am Fam Physician"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/sj.ki.5002180","article-title":"Phenotypic transitions and fibrosis in diabetic nephropathy","volume":"71","author":"Simonson","year":"2007","journal-title":"Kidney Int"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/bcp.12104","article-title":"Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney disease","volume":"76","author":"Cravedi","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1007\/s00125-018-4669-0","article-title":"The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure","volume":"61","author":"Thomas","year":"2018","journal-title":"Diabetologia"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12933-017-0654-z","article-title":"SGLT-2-inhibition with Dapagliflozin reduces tissue sodium content: a randomised controlled trial","volume":"17","author":"Karg","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/dom.13126","article-title":"Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis","volume":"20","author":"Hallow","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"101285","DOI":"10.1016\/j.diabet.2021.101285","article-title":"The diuretic effects of SGLT2 inhibitors: a comprehensive review of their specificities and their role in renal protection","volume":"47","author":"Delanaye","year":"2021","journal-title":"Diabetes Metab"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"4891","DOI":"10.1093\/eurheartj\/ehab497","article-title":"Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial","volume":"42","author":"Neuen","year":"2021","journal-title":"Eur Heart J"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ejim.2022.03.031","article-title":"Sodium glucose cotransporter-2 inhibitors protect the cardiorenal axis: update on recent mechanistic insights related to kidney physiology","volume":"100","author":"Ruiten","year":"2022","journal-title":"Eur J Intern Med"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"800490","DOI":"10.3389\/fphar.2022.800490","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on water and sodium metabolism","volume":"13","author":"Tang","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials","volume":"145","author":"Neuen","year":"2022","journal-title":"Circulation"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/s41577-020-00491-x","article-title":"Regulation of inflammation by the antioxidant Haem oxygenase 1","volume":"21","author":"Campbell","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3390\/biom11040589","article-title":"Heme oxygenase-1 signaling and redox homeostasis in physiopathological conditions","volume":"11","author":"Consoli","year":"2021","journal-title":"Biomol Ther"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"112169","DOI":"10.1016\/j.biopha.2021.112169","article-title":"Effects of SGLT2 inhibitors on ion homeostasis and oxidative stress associated mechanisms in heart failure","volume":"143","author":"Gager","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"8777","DOI":"10.3390\/ijms23158777","article-title":"Canagliflozin inhibits human endothelial cell inflammation through the induction of Heme oxygenase-1","volume":"23","author":"Peyton","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"174715","DOI":"10.1016\/j.ejphar.2021.174715","article-title":"Dapagliflozin exerts anti-inflammatory effects via inhibition of LPS-induced TLR-4 overexpression and NF-\u03baB activation in human endothelial cells and differentiated macrophages","volume":"918","author":"Abdollahi","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"820541","DOI":"10.3389\/fphar.2022.820541","article-title":"Canagliflozin ameliorates NLRP3 Inflammasome-mediated inflammation through inhibiting NF-\u03baB signaling and upregulating Bif-1","volume":"13","author":"Niu","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.3390\/biomedicines10102458","article-title":"SGLT2 inhibitors in chronic kidney disease: from mechanisms to clinical practice","volume":"10","author":"Skrabic","year":"2022","journal-title":"Biomedicines"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.3390\/ijms23063107","article-title":"SGLT-2 inhibitors in NAFLD: expanding their role beyond diabetes and cardioprotection","volume":"23","author":"Androutsakos","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s00125-022-05815-1","article-title":"Ketones: the double-edged sword of SGLT2 inhibitors?","volume":"66","author":"Lupsa","year":"2023","journal-title":"Diabetologia"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nm.3804","article-title":"The ketone metabolite \u03b2-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease","volume":"21","author":"Youm","year":"2015","journal-title":"Nat Med"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1007\/s00125-019-4859-4","article-title":"Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease","volume":"62","author":"Heerspink","year":"2019","journal-title":"Diabetologia"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.kint.2018.05.002","article-title":"A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice","volume":"94","author":"Zhang","year":"2018","journal-title":"Kidney Int"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"840","DOI":"10.3389\/fphys.2018.00840","article-title":"Elevated oxidative stress and inflammation in hypothalamic paraventricular nucleus are associated with sympathetic excitation and hypertension in rats exposed to chronic intermittent hypoxia","volume":"9","author":"Li","year":"2018","journal-title":"Front Physiol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1753944720939383","DOI":"10.1177\/1753944720939383","article-title":"Sodium glucose cotransporter (SGLT)-2 inhibitors alleviate the renal stress responsible for sympathetic activation","volume":"14","author":"Sano","year":"2020","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1161\/01.HYP.0000231307.69761.2e","article-title":"Oxidative stress mediates the stimulation of sympathetic nerve activity in the phenol renal injury model of hypertension","volume":"48","author":"Ye","year":"2006","journal-title":"Hypertension (Dallas, Tex: 1979)"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/s41440-023-01522-5","article-title":"Inhibiting SGLTs diminishes sympathetic output by reducing rostral ventrolateral medulla (RVLM) neuron activity","volume":"47","author":"Rahman","year":"2024","journal-title":"Hypertens Res"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11886-019-1165-1","article-title":"Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure","volume":"21","author":"Scheen","year":"2019","journal-title":"Curr Cardiol Rep"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"8786","DOI":"10.3390\/ijms22168786","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on vascular cell function and arterial remodeling","volume":"22","author":"Durante","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"114276","DOI":"10.1016\/j.bcp.2020.114276","article-title":"The sodium-glucose Cotransporter-2 (SGLT2) inhibitors synergize with nitric oxide and prostacyclin to reduce human platelet activation","volume":"182","author":"Lescano","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1002\/ehf2.13645","article-title":"SGLT2 inhibitors and cardiac remodelling: a systematic review and meta-analysis of randomized cardiac magnetic resonance imaging trials","volume":"8","author":"Dhingra","year":"2021","journal-title":"ESC Heart Fail"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14857","article-title":"2024 update in heart failure","author":"Beghini","year":"2024","journal-title":"ESC Heart Fail"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.jacc.2023.12.024","article-title":"2024 ACC expert consensus decision pathway for treatment of heart failure with reduced ejection fraction","volume":"83","author":"Maddox","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMc1712572","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1210\/er.2003-0018","article-title":"From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors\/cytokines","volume":"25","author":"Schrijvers","year":"2004","journal-title":"Endocr Rev"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13098-019-0403-4","article-title":"Diabetic nephropathy: recent advances in pathophysiology and challenges in dietary management","volume":"11","author":"Sulaiman","year":"2019","journal-title":"Diabetol Metab Syndr"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"e0158765","DOI":"10.1371\/journal.pone.0158765","article-title":"Global prevalence of chronic kidney disease \u2013 a systematic review and meta-analysis","volume":"11","author":"Hill","year":"2016","journal-title":"Plos One"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1093\/ndt\/gfae029","article-title":"SGLT2 inhibitors: approved for adults and cats but not for children with CKD","volume":"39","author":"Gross","year":"2024","journal-title":"Nephrol Dial Transpl"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","article-title":"Effects of SGLT2 inhibitors on kidney and cardiovascular function","volume":"83","author":"Vallon","year":"2021","journal-title":"Annu Rev Physiol"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"1479164120953625","DOI":"10.1177\/1479164120953625","article-title":"Risk of orthostatic hypotension associated with sodium-glucose cotransporter-2 inhibitor treatment: a meta-analysis of randomized controlled trials","volume":"17","author":"Rong","year":"2020","journal-title":"Diab Vasc Dis Res"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1053\/j.ajkd.2018.03.022","article-title":"SGLT2 inhibition for the prevention and treatment of diabetic kidney disease: a review","volume":"72","author":"Alicic","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/oby.22066","article-title":"The association between the dosage of SGLT2 inhibitor and weight reduction in type 2 diabetes patients: a meta-analysis","volume":"26","author":"Cai","year":"2018","journal-title":"Obesity (Silver Spring, Md)"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","article-title":"Efficacy and safety of Canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial","volume":"382","author":"Cefalu","year":"2013","journal-title":"Lancet (London, England)"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/oby.23331","article-title":"SGLT inhibitors on weight and body mass: a meta-analysis of 116 randomized-controlled trials","volume":"30","author":"Cheong","year":"2022","journal-title":"Obesity (Silver Spring, Md)"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/dom.12459","article-title":"Long-term glycaemic response and tolerability of Dapagliflozin versus a Sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data","volume":"17","author":"Del Prato","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/dom.14234","article-title":"Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add-on to metformin in patients with type 2 diabetes","volume":"23","author":"Inzucchi","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"e0279889","DOI":"10.1371\/journal.pone.0279889","article-title":"Effect of SGLT-2 inhibitors on body composition in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials","volume":"17","author":"Pan","year":"2022","journal-title":"PLoS One"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S2213-8587(14)70120-2","article-title":"Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial","volume":"2","author":"Ridderstr\u00e5le","year":"2014","journal-title":"Lancet Diab Endocrinol"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"e001956","DOI":"10.1136\/bmjdrc-2020-001956","article-title":"SGLT2 inhibitors in patients with type 2 diabetes with non-alcoholic fatty liver diseases: an umbrella review of systematic reviews","volume":"8","author":"Shao","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/jgh3.12473","article-title":"Meta-analysis of the effects of sodium glucose cotransporter 2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes","volume":"5","author":"Sinha","year":"2021","journal-title":"JGH Open Access J Gastroenterol Hepatol"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1007\/s12325-020-01498-5","article-title":"Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: a randomized, double-blind, placebo-controlled trial","volume":"37","author":"Taheri","year":"2020","journal-title":"Adv Ther"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3164\/jcbn.20-129","article-title":"Comparison of Dapagliflozin and teneligliptin in nonalcoholic fatty liver disease patients without type 2 diabetes mellitus: a prospective randomized study","volume":"68","author":"Tobita","year":"2021","journal-title":"J Clin Biochem Nutr"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"635556","DOI":"10.3389\/fendo.2021.635556","article-title":"Effect of SGLT2 inhibitors on type 2 diabetes mellitus with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials","volume":"12","author":"Wei","year":"2021","journal-title":"Front Endocrinol"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"609135","DOI":"10.3389\/fendo.2020.609135","article-title":"Sodium-glucose co-transporter 2 inhibitors for non-alcoholic fatty liver disease in Asian patients with type 2 diabetes: a meta-analysis","volume":"11","author":"Wong","year":"2020","journal-title":"Front Endocrinol"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1111\/jdi.13237","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"11","author":"Xing","year":"2020","journal-title":"J Diab Invest"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.3390\/cells11193107","article-title":"Anti-inflammatory properties of the SGLT2 inhibitor Empagliflozin in activated primary microglia","volume":"11","author":"Heimke","year":"2022","journal-title":"Cells"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"111709","DOI":"10.1016\/j.intimp.2024.111709","article-title":"Implication of M2 macrophage on NLRP3 inflammasome signaling in mediating the neuroprotective effect of canagliflozin against methotrexate-induced cognitive impairment","volume":"130","author":"Khedr","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"148536","DOI":"10.1016\/j.brainres.2023.148536","article-title":"Sodium-dependent glucose co-transporter-2 inhibitor empagliflozin exerts neuroprotective effects in rotenone-induced Parkinson\u2019s disease model in zebrafish; mechanism involving ketogenesis and autophagy","volume":"1820","author":"\u00dcnal","year":"2023","journal-title":"Brain Res"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"106062","DOI":"10.1016\/j.phrs.2022.106062","article-title":"Cognitive impairment and type 2 diabetes mellitus: focus of SGLT2 inhibitors treatment","volume":"176","author":"Rizzo","year":"2022","journal-title":"Pharmacol Res"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1515\/jom-2020-0153","article-title":"SGLT2 inhibitors: a narrative review of efficacy and safety","volume":"121","author":"Nelinson","year":"2021","journal-title":"J Osteopathic Med"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2886","article-title":"Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: basic mechanisms and therapeutic perspectives","volume":"33","author":"Qiu","year":"2017","journal-title":"Diabetes Metab Res Rev"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jcjd.2022.12.003","article-title":"Peri-colonoscopy implications of sodium-glucose cotransporter-2 inhibitor therapy: a mini-review of available evidence","volume":"47","author":"Thiruvenkatarajan","year":"2023","journal-title":"Can J Diabetes"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"e022577","DOI":"10.1136\/bmjopen-2018-022577","article-title":"Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis","volume":"9","author":"Donnan","year":"2019","journal-title":"BMJ Open"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1038\/s41598-017-02733-w","article-title":"Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"7","author":"Liu","year":"2017","journal-title":"Sci Rep"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","year":"2022","journal-title":"Lancet (London, England)"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1056\/NEJMc2118470","article-title":"Empagliflozin in heart failure with a preserved ejection fraction. Reply","volume":"386","author":"Anker","year":"2022","journal-title":"N Engl J Med"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1056\/NEJMc2301923","article-title":"Empagliflozin in patients with chronic kidney disease. Reply","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1056\/NEJMc1917241","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction. Reply","volume":"382","author":"McMurray","year":"2020","journal-title":"N Engl J Med"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5326\/JAAHA-MS-6822","article-title":"2018 AAHA diabetes management guidelines for dogs and cats*","volume":"54","author":"Behrend","year":"2018","journal-title":"J Am Anim Hosp Assoc"},{"key":"ref101","author":"Vieira","year":""},{"key":"ref102","doi-asserted-by":"publisher","first-page":"247","DOI":"10.5326\/JAAHA-MS-6101","article-title":"Owner experiences in treating dogs and cats diagnosed with diabetes mellitus in the United States","volume":"50","author":"Aptekmann","year":"2014","journal-title":"J Am Anim Hosp Assoc"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1111\/j.1939-1676.2010.0579.x","article-title":"Evaluation of a quality-of-life tool for cats with diabetes mellitus","volume":"24","author":"Niessen","year":"2010","journal-title":"J Vet Intern Med"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/vetsci4020027","article-title":"The big pet diabetes survey: perceived frequency and triggers for euthanasia","volume":"4","author":"Niessen","year":"2017","journal-title":"Vet Sci"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3390\/vetsci10030203","article-title":"Monitoring of diabetes mellitus using the flash glucose monitoring system: the owners\u2019 point of view","volume":"10","author":"Re","year":"2023","journal-title":"Vet Sci"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.rvsc.2016.04.001","article-title":"Effect of acarbose, sitagliptin and combination therapy on blood glucose, insulin, and incretin hormone concentrations in experimentally induced postprandial hyperglycemia of healthy cats","volume":"106","author":"Mori","year":"2016","journal-title":"Res Vet Sci"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1892\/0891-6640(2004)18<18:eotoad>2.0.co;2","article-title":"Evaluation of the oral antihyperglycemic drug metformin in normal and diabetic cats","volume":"18","author":"Nelson","year":"2004","journal-title":"J Vet Intern Med"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.domaniend.2014.04.006","article-title":"Effects of sitagliptin on plasma incretin concentrations after glucose administration through an esophagostomy tube or feeding in healthy cats","volume":"49","author":"Nishii","year":"2014","journal-title":"Domest Anim Endocrinol"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.rvsc.2014.12.001","article-title":"Effects of the glucagon-like peptide-1 (GLP-1) analogues exenatide, exenatide extended-release, and of the dipeptidylpeptidase-4 (DPP-4) inhibitor sitagliptin on glucose metabolism in healthy cats","volume":"99","author":"Padrutt","year":"2015","journal-title":"Res Vet Sci"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/j.1365-2885.2011.01341.x","article-title":"Pharmacokinetics of pioglitazone in lean and obese cats","volume":"35","author":"Clark","year":"2012","journal-title":"J Vet Pharmacol Ther"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/jvim.12255","article-title":"Effects of pioglitazone on insulin sensitivity and serum lipids in obese cats","volume":"28","author":"Clark","year":"2014","journal-title":"J Vet Intern Med"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"772","DOI":"10.2460\/javma.1997.210.06.772","article-title":"Intensive 50-week evaluation of glipizide administration in 50 cats with previously untreated diabetes mellitus","volume":"210","author":"Feldman","year":"1997","journal-title":"J Am Vet Med Assoc"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"821","DOI":"10.2460\/javma.1993.203.06.0821","article-title":"Effect of an orally administered sulfonylurea, glipizide, for treatment of diabetes mellitus in cats","volume":"203","author":"Nelson","year":"1993","journal-title":"J Am Vet Med Assoc"},{"key":"ref114","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/s0195-5616(95)50056-7","article-title":"NIDDM in the cat: treatment with the Oral hypoglycemic medication, glipizide","volume":"25","author":"Ford","year":"1995","journal-title":"Vet Clin North Am Small Anim Pract"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"106532","DOI":"10.1016\/j.domaniend.2020.106532","article-title":"Amyloidogenesis of feline amylin and plasma levels in cats with diabetes mellitus or pancreatitis","volume":"74","author":"Jotha-Mattos","year":"2021","journal-title":"Domest Anim Endocrinol"},{"key":"ref116","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0034-5288(92)90007-o","article-title":"Effect of glipizide on serum insulin and glucose concentrations in healthy cats","volume":"52","author":"Miller","year":"1992","journal-title":"Res Vet Sci"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/S1262-3636(14)72693-X","article-title":"Adverse effects and safety of SGLT-2 inhibitors","volume":"40","author":"Halimi","year":"2014","journal-title":"Diabetes Metab"},{"key":"ref118","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/jvp.12467","article-title":"Effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor Velagliflozin, a new drug with therapeutic potential to treat diabetes in cats","volume":"41","author":"Hoenig","year":"2018","journal-title":"J Vet Pharmacol Ther"},{"key":"ref119","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1111\/jvim.16902","article-title":"Velagliflozin, an SGLT2 inhibitor, as once-daily, Oral solution, stand-alone therapy for feline diabetes mellitus","volume":"37","author":"Behrend","year":"2023","journal-title":"J Vet Internal Med"},{"key":"ref120","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1111\/jvim.17124","article-title":"Efficacy and safety of once daily oral administration of sodium-glucose cotransporter-2 inhibitor velagliflozin compared with twice daily insulin injection in diabetic cats","volume":"38","author":"Niessen","year":"2024","journal-title":"J Vet Intern Med"},{"key":"ref121","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.cvsm.2012.11.002","article-title":"Diabetes and the kidney in human and veterinary medicine","volume":"43","author":"Bloom","year":"2013","journal-title":"Vet Clin North Am Small Anim Pract"},{"key":"ref122","first-page":"52","article-title":"Evaluation of Bexagliflozin in cats with poorly regulated diabetes mellitus","volume":"86","author":"Benedict","year":"2022","journal-title":"Can J Vet Res"},{"key":"ref123","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1111\/jvim.16730","article-title":"Safety and effectiveness of the sodium-glucose cotransporter inhibitor Bexagliflozin in cats newly diagnosed with diabetes mellitus","volume":"37","author":"Hadd","year":"2023","journal-title":"J Vet Intern Med"},{"key":"ref124","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/jvp.13466","article-title":"SGLT2 inhibitor use in the management of feline diabetes mellitus","volume":"48","author":"Cook","year":"2025","journal-title":"J Vet Pharmacol Ther"},{"key":"ref125","article-title":"The role of sodium\u2013glucose cotransporter 2 inhibitors in feline diabetes mellitus management","author":"Scott-Moncrieff","year":"2024","journal-title":"Today\u2019s Vet Pract"},{"key":"ref126","first-page":"193","article-title":"CANVAS and EMPA-REG findings support cardiovascular safety of SGLT2 inhibitors","volume":"21","author":"Hill","year":"2017","journal-title":"J Diabetes Nurs"},{"key":"ref127","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/ilar.47.3.234","article-title":"Feline models of type 2 diabetes mellitus","volume":"47","author":"Henson","year":"2006","journal-title":"ILAR J"},{"key":"ref128","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1002\/vetr.3","article-title":"Cognitive dysfunction in cats: update on neuropathological and behavioural changes plus clinical management","volume":"188","author":"Sordo","year":"2021","journal-title":"Vet Rec"},{"key":"ref129","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1177\/193229681200600306","article-title":"The cat as a model for human obesity and diabetes","volume":"6","author":"Hoenig","year":"2012","journal-title":"J Diabetes Sci Technol"},{"key":"ref130","doi-asserted-by":"publisher","first-page":"106376","DOI":"10.1016\/j.domaniend.2019.07.004","article-title":"The effect of the sodium-glucose cotransporter type-2 inhibitor Dapagliflozin on glomerular filtration rate in healthy cats","volume":"70","author":"Gal","year":"2020","journal-title":"Domest Anim Endocrinol"}],"container-title":["Frontiers in Veterinary Science"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2025.1480977\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T07:16:09Z","timestamp":1740726969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2025.1480977\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":130,"alternative-id":["10.3389\/fvets.2025.1480977"],"URL":"https:\/\/doi.org\/10.3389\/fvets.2025.1480977","relation":{},"ISSN":["2297-1769"],"issn-type":[{"value":"2297-1769","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]},"article-number":"1480977"}}